NASDAQ:CRSP

Crispr Therapeutics Stock News

etoro logo Buy CRSP
*Your capital is at risk
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks.

3 Dirt Cheap Stocks to Buy Right Now

07:36am, Saturday, 21'st Sep 2024
CRISPR Therapeutics is still in its early stages of growth. Gilead Sciences remains an underrated stock.
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $49.49, denoting a -0.2% change from the preceding trading day.
CRISPR Therapeutics is in the process of building out a network of clinics. As those clinics open up, it'll be able to realize more revenue from its therapy.

Crispr Therapeutics: Prepare To Be Bored

09:11am, Wednesday, 18'th Sep 2024
CRISPR Therapeutics' stock may seem boring due to the slow FDA trial and rollout process, but it's a strong long-term investment. CASGEVY, their FDA-approved treatment for sickle cell disease and TDT,

1 Biotech Stock Down 62% to Buy and Hold

08:45am, Thursday, 12'th Sep 2024
CRISPR Therapeutics' lone approved product boasts multibillion-dollar revenue potential. Plus, this promising biotech could succeed in launching other breakthrough therapies.
These companies are innovators and either already have at least one commercialized product or are close to the finish line. One of these players has climbed this year, while the other two have decline
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $45.51, representing a +1.42% change from its previous close.

2 Biotech Bets to Buy in September

12:32pm, Sunday, 08'th Sep 2024
Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair.
CRISPR recently obtained approval for Casgevy, a gene-editing therapy which may generate huge revenue. It could take years, however, before the biotech's bottom line starts to show significant improve
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?

3 Monster Biotech Stocks to Buy Before 2025

06:15pm, Monday, 02'nd Sep 2024
Iovance Biotherapeutics is seeing its sales ramp up for the first time. CRISPR Therapeutics has also started to bring in solid revenue.
Viking and CRISPR are both doing work in expanding and lucrative areas. They could deliver market-beating returns if they can avoid major headwinds.
Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.
CRISPR Therapeutics' stock has been volatile, with cautious optimism following FDA approval for gene therapy targeting sickle cell disease. Q2 2024 earnings revealed slow commercialization of Casgevy,
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE